? ? This SBIR project describes a novel method to create transgenic poultry that will produce biopharmaceutical proteins in their eggs. Poultry, including chickens and quail, are able to produce large amounts of protein in their eggs at relatively low cost. We seek to harness this capability to synthesize pharmaceutical proteins, such as humanized monoclonal antibodies, that are needed in large amounts. The efficiency of transgenesis in avians, particularly with large transgenes, is exceedingly low. We propose here to overcome this hurdle by the use of integration-promoting enzymes, which are able to recombine specific DNA sequences with a high efficiency. In Phase I of this project we will optimize the activity of integration promoting enzymes so that it is applicable in the early avian embryo. We will also evaluate the integration of large transgenes (i.e. up to 190 kilobasepairs), including bacterial artificial chromosomes. In Phase II of this project, the integration-promoting enzymes will be used to insert transgenes encoding pharmaceutical proteins, and driven by egg white specific promoters, into the genome of poultry. This novel technology will expedite the creation of poultry that can produce pharmaceuticals, thereby facilitating drug development, enhancing clinical trials and lowering the cost of pharmaceuticals. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM068139-01A1
Application #
6736593
Study Section
Special Emphasis Panel (ZRG1-SSS-Y (12))
Program Officer
Wolfe, Paul B
Project Start
2004-01-15
Project End
2004-06-14
Budget Start
2004-01-15
Budget End
2004-06-14
Support Year
1
Fiscal Year
2004
Total Cost
$90,000
Indirect Cost
Name
Synageva Biopharma Corporation
Department
Type
DUNS #
967296187
City
Lexington
State
MA
Country
United States
Zip Code
02421